Advent Pharma Ltd., an animal healthcare drugs manufacturer, has received approval from the Directorate General of Drug Administration recently to introduce five new products.
Of the new products, four are liquid items and the other is a powder item, according to an official disclosure.
The details of the products could not be known immediately.
The Advent Pharma is engaged in manufacturing, importing and marketing of animal healthcare drugs, nutritional supplements and feed additives for livestock such as powder, bolus and liquid dosage forms.
The company was listed on the Dhaka Stock Exchange (DSE) in 2018.
The company raised a fund worth Tk 200 million from the capital market by offloading 20 million ordinary shares of Tk 10 each using the fixed-price method.
Each share of the company closed at Tk 22.80 on March 25, the last trading session before the government holiday.
In the last one year, its share traded between Tk 18.90 and Tk 36.40 each.
The company has reported a profit of Tk 95.36 million in six months for July-December, 2019.
The company also reported earnings per share (EPS) of Tk 1.15 for July-December 2019 as against Tk 1.07 for July-December 2018.
Its net operating cash flow per share (NOCFPS) was Tk 1.35 for July-December 2019 as against Tk 1.49 for July-December 2018.
The net asset value (NAV) per share was Tk 13.24 as on December 31, 2019 and Tk 13.50 as on June 30, 2019.
The company disbursed 2.0 per cent cash and 10 per cent stock dividend for the year ended on June 30, 2019.
In 2018, the company also disbursed 2.0 per cent cash and 10 per cent stock dividend.
The company's paid-up capital is Tk 830.06 million and authorised capital is Tk 1.0 billion while total number of securities is 83 million.
The sponsor-director own 31.44 per cent stake in the company, while the institutional investors own 24.51 per cent and the general public 44.05 per cent as on February 29, 2020, the DSE data showed.
The company was incorporated as a private limited company in January 2007 and subsequently converted into a public limited company in May 2016.
